Galectin Therapeutics
GALT
50 hedge funds and large institutions have $4.85M invested in Galectin Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.
1,181% more call options, than puts
Call options by funds: $730K | Put options by funds: $57K
14% less funds holding
Funds holding: 58 → 50 (-8)
17% less capital invested
Capital invested by funds: $5.88M → $4.85M (-$1.02M)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
+$107K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$67K |
| 3 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$11K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$8.3K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$4.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCCM
Blue Clay Capital Management
Minneapolis,
Minnesota
|
-$122K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$53K |
| 3 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$46K |
| 4 |
SIM
Spark Investment Management
New York
|
-$39K |
| 5 |
BTS
BB&T Securities
Richmond,
Virginia
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$1.52K | -1,134 | -86% |
|
GALT Hedge Fund Activity: Q1 2016 in Review
50 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2016, worth a combined $4.85M — down 17% from $5.88M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GALT and 1 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was American International Group, adding an estimated $107K. The largest seller was Blue Clay Capital Management, exiting entirely with an estimated $122K sold.
- 50 institutional investors held Galectin Therapeutics (GALT) as of Q1 2016, down from 58 in Q4 2015.
- Funds reported $4.85M of Galectin Therapeutics stock for Q1 2016, down 17% quarter-over-quarter.
- 1 fund opened new Galectin Therapeutics positions in Q1 2016 and 7 closed out, a net change of -6 holders.
- The largest Galectin Therapeutics buyer in Q1 2016 was American International Group, an estimated $107K added.
- The largest Galectin Therapeutics seller in Q1 2016 was Blue Clay Capital Management, an estimated $122K sold.
Based on aggregated 13F filings for Q1 2016.